TY  - GEN
N2  - Psoriasis is a chronic, inflammatory disease that affects about 10 million individuals in the United States. New psoriasis treatments target the dysregulated immune system functions responsible for disease pathogenesis. However, many of these immune pathways are also responsible for protecting the body from fungal and bacterial infections. Due to the increasing number of biologic therapies recently approved to treat psoriasis, understanding the comparative infectious risk associated with different biologic therapies is of upmost importance.
DO  - 10.6083/8336h247h
DO  - DOI
AB  - Psoriasis is a chronic, inflammatory disease that affects about 10 million individuals in the United States. New psoriasis treatments target the dysregulated immune system functions responsible for disease pathogenesis. However, many of these immune pathways are also responsible for protecting the body from fungal and bacterial infections. Due to the increasing number of biologic therapies recently approved to treat psoriasis, understanding the comparative infectious risk associated with different biologic therapies is of upmost importance.
T1  - Another brick in the wall: building epidemiologic evidence of infectious risks by psoriasis therapy types
DA  - 2020
AU  - Rosenstein Siegel, Sarah A.
L1  - https://digitalcollections.ohsu.edu/record/7992/files/Siegel.Sarah.2020.pdf
PB  - Oregon Health and Science University
PY  - 2020
ID  - 7992
L4  - https://digitalcollections.ohsu.edu/record/7992/files/Siegel.Sarah.2020.pdf
KW  - Psoriasis
KW  - Patient Safety
KW  - Infections
KW  - biologic therapy
TI  - Another brick in the wall: building epidemiologic evidence of infectious risks by psoriasis therapy types
Y1  - 2020
L2  - https://digitalcollections.ohsu.edu/record/7992/files/Siegel.Sarah.2020.pdf
LK  - https://digitalcollections.ohsu.edu/record/7992/files/Siegel.Sarah.2020.pdf
UR  - https://digitalcollections.ohsu.edu/record/7992/files/Siegel.Sarah.2020.pdf
ER  -